Your browser doesn't support javascript.
loading
Fetal hemoglobin level predicts lower-risk myelodysplastic syndrome.
Hara, Ryujiro; Kitahara, Toshihiko; Numata, Hiroki; Toyosaki, Masako; Watanabe, Shigeki; Kikkawa, Eri; Ogawa, Yoshiaki; Kawada, Hiroshi; Ando, Kiyoshi.
Afiliación
  • Hara R; Department of Hematology, Ebina General Hospital, 1320 Kawaraguchi, Ebina, Kanagawa, 243-0433, Japan. ryujirohara@tokai-u.jp.
  • Kitahara T; Division of Hematology/Oncology, Department of Internal Medicine, Tokai University School of Medicine, Kanagawa, Japan. ryujirohara@tokai-u.jp.
  • Numata H; Department of Hematology, Ebina General Hospital, 1320 Kawaraguchi, Ebina, Kanagawa, 243-0433, Japan.
  • Toyosaki M; Department of Hematology, Ebina General Hospital, 1320 Kawaraguchi, Ebina, Kanagawa, 243-0433, Japan.
  • Watanabe S; Division of Hematology/Oncology, Department of Internal Medicine, Tokai University School of Medicine, Kanagawa, Japan.
  • Kikkawa E; Division of Hematology/Oncology, Department of Internal Medicine, Tokai University School of Medicine, Kanagawa, Japan.
  • Ogawa Y; Department of Hematology, Ebina General Hospital, 1320 Kawaraguchi, Ebina, Kanagawa, 243-0433, Japan.
  • Kawada H; Division of Hematology/Oncology, Department of Internal Medicine, Tokai University School of Medicine, Kanagawa, Japan.
  • Ando K; Division of Hematology/Oncology, Department of Internal Medicine, Tokai University School of Medicine, Kanagawa, Japan.
Int J Hematol ; 117(5): 684-693, 2023 May.
Article en En | MEDLINE | ID: mdl-36574168
The relationship between fetal hemoglobin (HbF) levels and disease prognosis in patients with myelodysplastic syndrome (MDS) is unclear. This study aimed to clarify the relationship between HbF level and the prognosis of MDS. To this end, data from 217 patients diagnosed with MDS between April 2006 and August 2020 at Ebina General Hospital were analyzed retrospectively. The primary endpoint was leukemia-free survival (LFS) for 5 years after diagnosis. HbF levels were significantly higher in patients with MDS than in control patients without MDS (n = 155), with a cut-off value of 0.4%. Higher-risk patients had a similar prognosis regardless of HbF level, but lower-risk patients had longer LFS at intermediate HbF levels. Although prognosis based on pre-treatment HbF levels did not differ significantly among azacitidine-treated patients, prognosis tended to be better in lower-risk patients with intermediate HbF levels. Multivariate analysis showed that the intermediate HbF category correlated with LFS, independently of MDS lower-risk prognostic scoring system (LR-PSS)-related factors. This study is the first to assess the association between HbF levels and the new World Health Organization 2016 criteria for MDS, demonstrating the significance of HbF levels in the prognosis of MDS.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Síndromes Mielodisplásicos / Hemoglobina Fetal Tipo de estudio: Etiology_studies / Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Int J Hematol Asunto de la revista: HEMATOLOGIA Año: 2023 Tipo del documento: Article País de afiliación: Japón Pais de publicación: Japón
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Síndromes Mielodisplásicos / Hemoglobina Fetal Tipo de estudio: Etiology_studies / Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Int J Hematol Asunto de la revista: HEMATOLOGIA Año: 2023 Tipo del documento: Article País de afiliación: Japón Pais de publicación: Japón